Gustavo A.A. Santos, P. Pardi
Mar 30, 2021
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
Journal name not available for this finding
Abstract
Objectives: To prove the therapeutic efficacy of rivastigmine tartrate in transdermal form, for the reduction of blood esterase levels, in patients with Alzheimer's disease. Methods: Forty AD patients were treated with Rivastigmine and evaluated for serum levels of AChE and BuChE esterases for 180 days. Results: We found that serum levels of BuChE in the transdermal group were significantly different (p <0.0004) than in the oral group at 90 days. Conclusion: Rivastigmine significantly reduced BuChE levels in patients with AD.